Hit to Lead for the Antiviral Drug Discovery of Coronavirus
At present, the drug research for treating Coronavirus Disease 2019 (COVID-19) has just started, and there is a lack of selective therapeutic drugs in clinical practice. It is urgent to find and develop new treatment methods and drugs. In the face of urgent outbreaks, it is an efficient strategy to screen potential drug candidates from old drugs that are already on the market or from active molecules in clinical trials. Considering the threat of coronavirus infection to humans, we should not only actively seek specific antiviral drugs, but also promote the development of new broad-spectrum anti-coronavirus drugs. After hit identification, Creative Biostructure provides a full range of <a href="https://www.creative-biostructure.com/coronavirus/hit-to-lead-for-the-antiviral-drug-discovery-of-coronavirus-p22.htm">hit-to-lead services</a> to support your antiviral drug discovery project against coronavirus infection.
By using a parallel evaluation approach, the process of hit to lead can be accelerated. Through this phase, the range of compounds requiring further optimization is narrowed. After discussions with the customer, scientists at Creative Biostructure will ultimately determine whether these hits are suitable for subsequent optimization studies. Our customer service representative is available 24 hours a day from Monday to Sunday. If you have any questions, please feel free to contact us.
After screening out the compounds showing potential activity against the target through the hit identification stage, it is necessary to carry out further characterization and optimization of these hit compounds. And this stage is termed as hit to lead. The goal of this stage is to identify the most promising hit series through limited structure-activity relationship (SAR) studies to enter the lead optimization and preclinical development stage. With a dedicated team of skilled scientists and technicians, Creative Biostructure provides MagHelix™ hit evaluation and lead identification (hit to lead) solutions to meet our clients’ needs and goals.Whether your therapeutic goal focuses on the development of small molecules, peptides, or other biologics, Creative Biostructure can ensure that the performance of your initial hits is significantly improved to meet the standards required to enter the lead optimization stage.
We can prioritize and classify the hit compounds identified through screening platforms and utilize advanced biophysical techniques to analyze the target-ligand binding modes. In addition, computer-aided drug design (CADD) tools can help you perform pharmacophore modeling, QSAR analysis, ADME/T prediction, etc. The molecules after the hit to lead stage are the most likely potential leads, which have enhanced potency, reduced off-target activity, and predicted physiochemical/metabolic properties of reasonable in vivo pharmacokinetics.
Service Research： <a href="https://drug-discovery.creative-biostructure.com/hit-to-lead-p44">hit to lead process</a>